SUVEN
Suven Life Sciences share price & financials
- Price
- ₹325.9
- Market cap
- ₹10.0k Cr
- Sector
- Healthcare
- Calls analysed
- 5
Suven Life Scie. Q3 FY20
SLS Book Value ₹390 cr; SPL Book Value ₹806 cr; SLS Cash ₹150 cr. Suven Life Sciences (SLS) SUVN-502 failed primary endpoint but secondary data promising for new indications, targeting new clinical trial.
Read the full call →What Suven Life Sciences Limited does
Suven Life Sciences discovers and develops New Chemical Entities (NCEs) targeting Central Nervous System (CNS) disorders such as Alzheimer's disease, schizophrenia, depression, narcolepsy and cognitive disorders. It does not manufacture or sell any approved drug; instead it earns through out-licensing, partnership/collaboration deals and eventual commercialisation of its pipeline molecules once they clear clinical trials. Its wholly-owned US subsidiary, Suven Neurosciences Inc. (Delaware), runs the clinical development and commercialisation of its NCE molecules in the United States. The company was formed via the 2020 demerger that hived off its earlier CRAMS (contract research and manufacturing) business into a separate listed entity, leaving Suven to focus solely on CNS drug discovery and development.
- CNS molecule pipeline
- 13 molecules
- Molecules in clinical trial phase
- 5 molecules
- Molecules in Phase 2/3 clinical trials
- 3 molecules
- Global patents held
- 2,850+ (expiring 2035 and beyond)
- Market position
- India's only CNS-focused, NCE (New Chemical Entity) developer
- US clinical subsidiary
- Suven Neurosciences, Inc. (Delaware, USA), est. 2015
Guidance record · Q3 FY20
what the last two calls moved 11 tracked 2 delivered 1 missed 8 open- SUVN-502 Data Release Timeline delivered said Q3 FY19 Promised: July 2019 Q3 FY20: we have a big disappointment with respect to the SUVN-502... it did not make the final end point
- FY20 Bottom-line Growth went quiet said Q3 FY19 Promised: 20-25% Q3 FY20: Not addressed in the call.
- FY20 Revenue Growth revised up said Q3 FY19 Promised: 15% Q3 FY20: So overall we will be giving a 20% to 22% growth compared to last year.
All 11 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 100.0%, net profit down 6.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 1 | 2 | 1 −67% | 3 +50% | 2 +100% | 4 +100% |
| EBITDA | -14 | -13 | -15 | -14 | -18 −29% | -15 −15% | -16 −7% | -21 −50% |
| Net profit | -11 | -13 | -15 | -15 | -15 −36% | -13 +0% | -11 +27% | -16 −7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +63.1% 1Y
1Y: ₹217.95 on 10 Sept 2025 → ₹355.55. High ₹392.05 (31 Aug 2026), low ₹126.65 (23 Mar 2026).
Financials, as filed
Revenue fell 17.0% a year over 3 years, FY23 to FY26. Operating margin widened to -787.5%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹11 Cr | ₹7 Cr | ₹8 Cr |
| Operating profit | ₹-127 Cr | ₹-31 Cr | ₹-52 Cr | ₹-63 Cr |
| Operating margin | -907.1% | -281.8% | -742.9% | -787.5% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹8 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr |
| Net profit | ₹-118 Cr | ₹-8 Cr | ₹-47 Cr | ₹-54 Cr |
| Net margin | -842.9% | -72.7% | -671.4% | -675.0% |
| Cash from operations | ₹-23 Cr | ₹-21 Cr | ₹-49 Cr | ₹-68 Cr |
| Free cash flow | ₹-26 Cr | ₹-18 Cr | ₹-86 Cr | ₹-73 Cr |
| ROCE | -4.0% | -2.0% | -6.0% | -6.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹13 Cr | ₹15 Cr | ₹22 Cr | ₹22 Cr | ₹23 Cr | ₹26 Cr |
| Reserves | ₹389 Cr | ₹461 Cr | ₹832 Cr | ₹824 Cr | ₹259 Cr | ₹1.5k Cr |
| Borrowings | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹17 Cr |
| Other liabilities | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹56 Cr | ₹11 Cr |
| Total liabilities | ₹415 Cr | ₹486 Cr | ₹860 Cr | ₹851 Cr | ₹337 Cr | ₹1.5k Cr |
| Fixed assets | ₹21 Cr | ₹38 Cr | ₹37 Cr | ₹28 Cr | ₹58 Cr | ₹73 Cr |
| Capital work in progress | ₹5 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹4 Cr |
| Investments | ₹295 Cr | ₹426 Cr | ₹528 Cr | ₹653 Cr | ₹247 Cr | ₹1.1k Cr |
| Other assets | ₹95 Cr | ₹19 Cr | ₹295 Cr | ₹170 Cr | ₹32 Cr | ₹361 Cr |
| Total assets | ₹415 Cr | ₹486 Cr | ₹860 Cr | ₹851 Cr | ₹337 Cr | ₹1.5k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jul 2026
Since Jun 2025, promoters trimmed −4.79 pp while DIIs added +2.70 pp.
- Promoters
- 65.5%
- FIIs
- 0.5%
- DIIs
- 2.7%
- Public
- 31.3%
Since Jun 2025
- Promoters −4.79 pp
- DIIs +2.70 pp
- Public +2.20 pp
How it drifted, 12 quarters
Over this window promoters fell from 69.6% to 65.5% — −4.1 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 69.6%, FIIs 0.5%, DIIs 0.0%, Public 29.9%.Mar '24: Promoters 69.6%, FIIs 0.5%, DIIs 1.1%, Public 28.9%.Jun '24: Promoters 70.3%, FIIs 0.5%, DIIs 1.1%, Public 28.2%.Sep '24: Promoters 70.3%, FIIs 0.3%, DIIs 1.1%, Public 28.3%.Dec '24: Promoters 70.3%, FIIs 0.3%, DIIs 1.1%, Public 28.4%.Mar '25: Promoters 70.3%, FIIs 0.3%, DIIs 0.0%, Public 29.5%.Jun '25: Promoters 70.3%, FIIs 0.6%, DIIs 0.0%, Public 29.1%.Sep '25: Promoters 67.4%, FIIs 1.2%, DIIs 3.4%, Public 28.1%.Dec '25: Promoters 67.4%, FIIs 1.1%, DIIs 3.4%, Public 28.2%.Mar '26: Promoters 70.2%, FIIs 0.9%, DIIs 4.6%, Public 24.3%.Jun '26: Promoters 70.1%, FIIs 0.6%, DIIs 2.9%, Public 26.4%.Jul '26: Promoters 65.5%, FIIs 0.5%, DIIs 2.7%, Public 31.3%.
Who is on the register
Named in the Jul 2026 filing
Every holder of Suven Life Sciences Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its Capacity as sole trustee of Jasti Family Trust) | 64.93% | −4.57 pp |
| 3p India Equity Fund 1 AIF | 1.19% | −0.08 pp |
| Abakkus Diversified Alpha Fund AIF | 1.00% | −0.07 pp |
| Sudharani Jasti | 0.54% | unchanged |
| Sirisha Jasti | 0.00% | unchanged |
| Madhavi Jasti | 0.00% | unchanged |
| Venkateswarlu Jasti | 0.00% | unchanged |
| Kalyani Jasti | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (5)
Read the Q3 FY20 call →Learn to analyse Suven Life Sciences Limited
Guides on how to read this kind of business and the numbers that matter.